• 作者：O. Laurent^a ; C. Caoduro^a ; S. Servagi-Vernat^b ; V. Westeel^c ; H. Boulahdour^a ; O. Blagosklonov^a ; ^{oleg.blagosklonov@univ-fcomte.fr}
• 关键词：Tomographie par é ; mission de positons ; 18F-fluorodesoxyglucose ; Carcinome bronchique non à ; petites cellules ; É ; valuation thé ; rapeutique ; Volumes cibles
• 刊名：Médecine Nucléaire
• 出版年：2012
• 出版时间：November, 2012
• 年：2012
• 卷：36
• 期：11
• 页码：655-662
• 全文大小：690 K

Currently ¹⁸F-FDG-PET is the gold standard to evaluate tumor response after chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC). PET can also determine the volumes to be treated by radiotherapy, in inoperable patients. The aim of our mixed (prospective and retrospective) study concerned 28 patients with NSCLC, was to quantify the variation of the metabolic activity of lesions and their volumes after chemotherapy. We also studied the impact of change of these volumes on the definition of radiotherapy target volumes. Patients with stage II-IV and inoperable NSCLC were included. Two PET scans were performed: before treatment (PET1), then after two to six courses of chemotherapy (PET2). Of the 28 patients included, we observed complete metabolic response in six patients (21 % ), partial metabolic response in 13 patients (46 % ), stable disease in seven patients (25 % ), and progressive metabolic disease in two patients (7 % ), according to the PERCIST criteria. We observed significant variation (P < 0.001) of metabolic activity (estimated by SULpeak or SUVmax) for primary tumor as well as for overall lesions between the two PET scans. Thus, the target volumes of radiotherapy decreased significantly (P < 0.01) in PET2. Our results confirm that ¹⁸F-FDG-PET is not only a powerful technique for treatment evaluation but also a useful tool for radiotherapy planning after chemotherapy, in the context of personalized treatments.